Table 2 SPARC expression in the primary tumor
High SPARC | Low SPARC | No SPARC | |
|---|---|---|---|
Histology | N = 22 | N = 13 | N = 15 |
UPS | 16 | 9 | 7 |
LMS | 2 | 2 | 2 |
LPS | 3 | 1 | 2 |
Dedifferentiated | 2 | 1 | 0 |
Pleomorphic/NOS | 1 | 0 | 1 |
Myxoid | 0 | 0 | 1 |
SS | 0 | 0 | 3 |
MPNST | 0 | 1 | 1 |
FS | 1 | 0 | 0 |
Treatment for primary prior to tumor collection | |||
Gemcitabine/docetaxel | 14 | 3 | 3 |
Doxorubicin/ifosfamide | 5 | 9 | 10 |
None | 3 | 1 | 3 |
Radiation | 0 | 1 | 1 |
% necrosis observed in tumor after chemotherapy | |||
UPS | 20–100 | 0–70 | 0–75 |
LMS | 50 | 80a | 30 |
LPS | |||
Dedifferentiated | 15–50 | 0 | NA |
Pleomorphic/NOS | 85 | NA | 10 |
Myxoid | NA | NA | 90 |
SS | NA | NA | 0–80a |
MPNST | NA | 5 | 40 |
FS | 10 | NA | NA |
Best Response to chemotherapy by RECIST 1.0 | |||
Partial response | 0 | 2 | 0 |
Stable disease | 19 | 8 | 14 |
Progressive disease | 3 | 3 | 1 |
Recurrence | 9 | 7 | 5 |
Local | 2 | 4 | 0 |
Distant | 7 | 3 | 5 |